Apyx Medical misses Q2 revenue estimates; raises FY25 guidance

Apyx Medical

07/08/2025 21:35

Overview

Apyx Medical Q2 revenue falls 6.4% yr/yr, missing analyst expectations, per LSEG data

Net loss narrows to $3.8 mln, adjusted EBITDA loss improves to $2.0 mln

Co raises FY2025 revenue guidance to $50-52 mln on strong AYON pre-sales

Outlook

Company raises FY2025 revenue guidance to $50.0 mln-$52.0 mln

Apyx expects Advanced Energy revenue of $42.0 mln-$44.0 mln for FY2025

Company projects OEM revenue at approximately $8.0 mln for FY2025

Apyx anticipates operating expenses below $40.0 mln for FY2025

Result Drivers

AYON LAUNCH - Successful launch of AYON Body Contouring System exceeded customer demand expectations, per CEO Charlie Goodwin

RENUVION IN CHINA - Strong clinical interest and initial procedures completed following Renuvion's commercial sales launch in China

OPERATING EXPENSES - Decrease in operating expenses contributed to a narrower net loss in Q2 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Miss
$11.37 mln
$11.70 mln (3 Analysts)
Q2 EPS
-$0.09
Q2 Net Income
-$3.74 mln
Q2 Adjusted EBITDA
Miss
-$1.96 mln
-$1.68 mln (2 Analysts)
Q2 Gross Margin
62.3%
Q2 Income From Operations
-$2.57 mln
Q2 Pretax Profit
-$3.69 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Apyx Medical Corp is $4.00, about 49% above its August 6 closing price of $2.04

Press Release: ID:nGNXbyjnFb

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)